TH-302

Catalog No.S2757

TH-302 is selective hypoxia-activated prodrug targeting hypoxic regions of solid tumors with IC50 of 19 nM, demonstrates 270-fold enhanced cytotoxicity under hypoxia versus their potency under aerobic conditions, stable to cytochrome P450 metabolism.

Availability

The item is temporarily out of stock. Please leave your email address and we will inform you when we have it in stock.

Just click the ‘Arrival Notice’ and leave your email address to get 10% off.

Arrival Notice
TH-302 Chemical Structure

TH-302 Chemical Structure
Molecular Weight: 449.04

Validation & Quality Control

Product Information

  • Compare Others
    Compare Others

Product Description

Biological Activity

Description TH-302 is selective hypoxia-activated prodrug targeting hypoxic regions of solid tumors with IC50 of 19 nM, demonstrates 270-fold enhanced cytotoxicity under hypoxia versus their potency under aerobic conditions, stable to cytochrome P450 metabolism.
Targets Hypoxic regions
IC50 19 nM [1]
In vitro TH-302 is selectively potent under hypoxia and stable to liver microsomes. Substitution of the chlorine with bromine on the phosphorus mustard in 3b increases the potency by 10-fold and maintaines the high hypoxic selectivity [Hypoxia cytotoxicity ratio (HCR) = 270]. In both human lung cancer H460 cells and human colon cancer HT29 cells, potent cytotoxicity of TH-302 is observed under N2. TH-302 inhibits H460 cells and HT29 cells with IC90 of 0.1 μM and 0.2 μM, respectively. [1] TH-302 shows much enhanced potency in H460 spheroids compared to H460 monolayer cells under normoxia. [2] TH-302 exhibits potent cytotoxicity to MM cells with hypoxic selectivity and dose dependency. TH-302 can induce G0/G1 cell-cycle arrest under hypoxic conditions. The effect of TH-302 on cell-cycle machinery is mediated by down-regulating cyclin D1/2/3, CDK4/6, p21cip-1, p27kip-1, and pRb expression, whereas CDK2 expression remained undisturbed. TH-302 can induce dose-dependent apoptosis in both human and murine MM cells in hypoxic conditions. TH-302-activated apoptosis is mediated through down-regulating the antiapoptotic proteins BCL-2 and BCL-xL, as well as up-regulating the expression of cleaved proapoptotic protein caspase-3, -8, and -9 and poly ADP-ribose polymerase. In contrast to the hypoxia-specific toxicity, TH-302 shows very low toxicity in normoxic condition, even at high concentrations. [3]
In vivo TH302 inhibits primary tumor growth by 41% on day 25 after implantation, whereas TH302 plus gemcitabine (a nucleoside analog) inhibits primary tumor growth by 96% on day 25. [1] When TH-302 is administered at 6.25, 12.5, 25, or 50 mg/kg in the H460 NSCLC xenograft model QD × 5/wk × 2 wks (once a day for 5 days per week for 2 weeks) i.p., the tumor growth inhibition at Day 22 is 43%, 51%, 75%, and 89%, respectively. TH-302 at 100 mg/kg shows a decrease in blood cell counts 3 days after treatment end, but is totally recovered 7 days post-treatment. TH-302 under all tested regimens exhibits efficacy metrics ranging from 58% to 89% tumor growth inhibition. TH-302 induced cell killing is breathing oxygen concentration dependent, with the greatest cytotoxicity occurring when the tumor-bearing mice are exposed to low oxygen concentrations. Tumor growth is significantly reduced by TH-302 in animals breathing 10% O2 compared with 95% O2 breathing. After TH-302 treatment, the pimonidazole-positive area is significantly decreased at 48 hours after dosing (6.3 % in vehicle vs. 1.8 % in the TH-302 treatment group). [4]
Features

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines Human H460 or HT29 cells
Concentrations 0.01 -1 μM
Incubation Time 2 hours
Method Exponentially growing human H460 or HT29 cells are seeded into 60 mm notched glass plates at 3 × 105 cells per plate and grown in RPMI medium supplemented with 10% fetal bovine serum for 2 days prior to initiating treatment. On the day of the test, TH-302 stocks of known concentrations are prepared in complete medium and 2 mL of the desired stock is added to each plate. The plates are placed in either an anaerobic chamber or a standard tissue-culture incubator. The anaerobic chamber is evacuated and gassed with the anaerobic gas mixture (90% N2/5% CO2/5% H2) to create a hypoxic environment. Cells are then incubated with TH-302 for 2 hours at 37 °C. At the end of treatment, plates are removed from each vessel and washed with phosphate-buffered saline and a solution of trypsin-EDTA and then trypsinized for 5 min at 37 °C. Detached cells are neutralized with medium plus serum and spun for 5 min at 100g. Cells are resuspended at approximately 1 × 106 cells/mL and diluted 10-fold for plating. The exact concentration of each stock is determined. Known numbers of cells are plated and placed undisturbed in an incubator for between 9 and 13 days. Colonies are fixed and stained with a solution of 95% ethanol with 0.25% crystal violet stain. Colonies of greater than 50 cells are counted, and the surviving fraction is determined. Plating efficiencies (PEs) are determined by dividing the number of colonies by the actual number of cells plated. Surviving fractions are calculated by dividing the PEs of treated cells by the PEs of untreate

Animal Study: [4]

Animal Models H460, Calu-6, PC-3, H82, A375, Stew2, 786-O, PLC/PRF/5, Hs766t, BxPC-3, and SU.86.86 xenografts are established in NCI SCID female mice.
Dosages 50 mg/kg
Administration Intraperitoneally
Solubility 30% propylene glycol, 5% Tween 80, 65% D5W, 30 mg/mL
1

References

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01522872 Recruiting Multiple Myeloma Threshold Pharmaceuticals 2012-02 Phase 1|Phase 2
NCT01746979 Recruiting Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma EMD Serono|Threshold Pharmaceuticals 2012-12 Phase 3
NCT01833546 Recruiting Solid Tumor|Pancreatic Cancer Merck KGaA|Threshold Pharmaceuticals 2013-04 Phase 1
NCT01864538 Not yet recruiting Metastatic Melanoma Threshold Pharmaceuticals 2013-05 Phase 2
NCT01721941 Not yet recruiting Hepatocellular Carcinoma Scripps Clinic Cancer Center|Threshold Pharmaceuticals 2013-07 Phase 1

Chemical Information

Download TH-302 SDF
Molecular Weight (MW) 449.04
Formula

C9H16Br2N5O4P

CAS No. 918633-87-1
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms N/A
Solubility (25°C) * In vitro DMSO mg/mL (<1 mM)
Water mg/mL (<1 mM)
Ethanol mg/mL (<1 mM)
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (1-methyl-2-nitro-1H-imidazol-5-yl)methyl N,N-bis(2-bromoethyl)phosphordiamidate

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Others

  • SRPIN340

    SRPIN340 is a selective SRPK inhibitor with Ki of 0.89 μM for SRPK1, showing no significant inhibitory activity against more than 140 other kinases..

    Features:The only specific SRPK1 and SRPK2 inhibitor. Potential use in congenital diseases and viral diseases including HIV, HCV and HBV.

  • RI-1

    RI-1 is a RAD51 inhibitor with IC50 ranging from 5 to 30 μM.

    Features:A selective recombinant RAD51 protein inhibitor discovered in 2012. Valuable tool for mechanistic studies of DNA repair and potential for use in many cancers.

  • OAC1

    OAC1 (Oct4-activating compound 1) can enhance the efficiency of reprogramming.

  • CX-4945 (Silmitasertib)

    CX-4945 is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM, less potent to Flt3, Pim1 and CDK1 (inactive in cell-based assay). Phase 1.

    Features:First clinical inhibitor of CK2.

  • Tacrolimus (FK506)

    FK-506 is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • Bendamustine HCl

    Bendamustine HCL is a DNA-damaging agent with IC50 of 50 μM.

  • Posaconazole

    Posaconazole is a sterol C14ɑ demethylase inhibitor with an IC50 of 0.25 nM.

    Features:Currently the most advanced candidate for the treatment of Chagas disease.

  • Cidofovir

    Cidofovir suppresses virus replication by selective inhibition of viral DNA synthesis.

  • Simvastatin

    Simvastatin is a competitive inhibitor of HMG-CoA reductase with Ki of 0.1-0.2 nM .

  • Streptozotocin (STZ)

    Streptozotocin is a glucosamine-nitrosourea derivative, which is a methylating, carcinogenic, antibiotic and diabetes inducing agent.

Recently Viewed Items

Tags: buy TH-302 | TH-302 supplier | purchase TH-302 | TH-302 cost | TH-302 manufacturer | order TH-302 | TH-302 distributor
Contact Us